Concizumab is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) for the prophylaxis of bleeding episodes in patients with hemophilia A or B. In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting factor.
- Mechanism
- Curator reviewed · 4 references
Concizumab is a monoclonal antibody antagonist specific for the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI). Under normal circumstances, TFPI acts to attenuate the coagulation cascade by inhibiting the extrinsic (aka initiation) coagulation pathway, allowing the intrinsic (aka amplification) pathway to take over. In patients with hemophilia - which is characterized by deficiencies in the intrinsic coagulation pathway - the inhibition of TFPI enhances the production of factor Xa during the initiation phase of the coagulation pathway, improving thrombin generation and clot formation.
- Primary indication
- Concizumab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years of age who have hemophilia A or B with or without inhibitors.Curator reviewed · 7 structured indications
- Formula / weight
- 149000.0 Da
- First approval
- Canada, 2023 · United States, 2025 · European Union, 2025
- Code names
- MAB-2021 · NN-7415 · NNC-0172-0000-2021 · NNC0172-2021 · NNC172-2021
Resolves to
What you can answer from here — as of October 21, 2025
Which drugs share a target with Concizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account